Proteomics News and Research

RSS

The term 'proteome' was first coined in 1994, and refers to all the proteins in a cell, tissue, or organism. Proteomics refers to the study of the proteome. Because proteins are involved in almost all biological activities, the proteome is a rich source of biological information.

NCI awards $4.8M for project to measure all the proteins in the human body

An expert in cancer proteomics at Fred Hutchinson Cancer Research Center has received $4.8 million in federal stimulus funding from the National Cancer Institute to co-lead a pilot study to assess the feasibility and scalability of a project that aims to measure all of the proteins in the human body.

31 Oct 2009

Celera to use Medical Therapies' midkine patent portfolio for development of novel lung cancer diagnostics

Celera Corporation, a health care company focused on genetics, and Medical Therapies Limited (ASX:MTY), a biotechnology company developing midkine-related diagnostic and therapeutic products, have entered into an exclusive license agreement for the use of MTY’s midkine patent portfolio for the development of novel lung cancer diagnostics.

30 Oct 2009

GeneGo to launch new web site with high quality pathway content

GeneGo, Inc., the leading systems biology tools company, announced today that they will be launching a new web site with FREE high quality pathway content. On www.genego.com, anyone can now search for genes, proteins, compounds, processes and diseases and access high quality manually curated pathway maps for human, mouse and rat signaling and metabolism.

29 Oct 2009

NCI awards UAMS Myeloma Institute $19.5M grant

The internationally known multiple myeloma program at the University of Arkansas for Medical Sciences (UAMS) will receive $19.5 million over five years to continue work that has already developed new treatments for this cancer of plasma cells, a type of white blood cell present in the bone marrow.

28 Oct 2009

Precision Antibody to develop antibodies for NCI's Clinical Proteomic Technologies for Cancer

Precision Antibody(TM) has been selected as the antibody developer for a component of the National Cancer Institute (NCI)'s Clinical Proteomic Technologies for Cancer (CPTC), which is focused on improving the number and standardizing the quality of monoclonal antibody reagents available for clinical cancer proteomics research.

28 Oct 2009

NCI funds pilot study to measure human proteins

28 Oct 2009

Genomics can provide insights in understanding emerging infectious disease

This week, the Public Library of Science, an open-access publisher, presents the "Genomics of Emerging Infectious Disease," a collection of essays, perspectives, and reviews that explores how genomics-with all its associated tools and techniques-can provide insights into our understanding of emerging infectious disease.

27 Oct 2009

Eurogentec to acquire Anaspec, a private proteomics company in California

Eurogentec S.A. (“Eurogentec”) announces today a final agreement for the acquisition of AnaSpec, Inc. (“AnaSpec” or the “Company”), a privately-held proteomics company based in Fremont, California.

24 Oct 2009

Dig Pink Volleyball Breast Cancer Awareness campaign to raise $1 million in support of breast cancer research

The Side-Out Foundation and its Dig Pink- Volleyball Breast Cancer Awareness campaign will launch a first of its kind clinical trial this month to examine the effects of individualized treatment on patients with metastatic breast cancer.

23 Oct 2009

Early diagnostic for ovarian cancer to be developed

BioProspecting NB Inc. (BPNBI) and the Atlantic Cancer Research Institute (ACRI) have established a formal collaboration to develop an early diagnostic for ovarian cancer based on BPNBI's unique, proprietary cancer management platform.

23 Oct 2009

Thermo Fisher Scientific's revenues decrease by 2% in third quarter 2009

Thermo Fisher Scientific Inc., the world leader in serving science, reported that revenues decreased 2% to $2.53 billion in the third quarter of 2009, compared with $2.59 billion in the 2008 quarter. These results reflect the impact of foreign currency translation, which lowered revenues by 2%, and acquisitions, which increased revenues by 2%. GAAP diluted earnings per share (EPS) were $.53 in 2009, versus $.50 in the year-ago period. GAAP operating income for the 2009 quarter was $275 million, compared with $286 million in 2008, and GAAP operating margin was 10.9%, compared with 11.1% a year ago.

From Thermo Fisher Scientific Inc. 22 Oct 2009

Protein Discovery and New Objective sign co-marketing and development agreement

Protein Discovery, Inc. and New Objective, Inc. today announced that they have entered into a strategic co-marketing and development agreement designed to enable and expand key applications for intact protein analysis using mass spectrometry ("top down" proteomics).

22 Oct 2009

Illumina announces 2010 roadmap for Infinium whole-genome genotyping platform

At the 59th annual meeting of the American Society of Human Genetics, Illumina, Inc. today announced its 2010 roadmap for the Infinium whole-genome genotyping platform, offering products capable of analyzing up to five million (5M) variants per sample.

From Illumina, Inc. 22 Oct 2009

Life science tool companies must consider multiple factors to develop strategies for future

Companies involved in the life science tools market must consider a multitude of technologies, economic drivers and societal trends in developing strategies for the future.

21 Oct 2009

New workflow automation system from Illumina

At the 59th annual meeting of the American Society of Human Genetics, Illumina, Inc. announced the launch and immediate availability of cBot, a new standard for ease-of-use and sequencing workflow automation.

From Illumina, Inc. 21 Oct 2009

UNC scientists receive GO grant to study the human genome blueprint

Ever since the first genome sequence was published in 2001, scientists have been working to figure out what the sequence means. An analogy is walking across a desert and finding a large book in a language you don't know, then trying to figure out what the book is saying.

19 Oct 2009

Illumina and Solexa deny patent infringement allegations

Illumina, Inc. today announced that, together with Solexa its wholly owned subsidiary, it has filed its initial response to the lawsuit brought by Life Technologies and Applied Biosystems on September 21, 2009 in U.S. District Court in Wilmington, Delaware. In their answer, Illumina and Solexa have denied all of Life’s and AB’s allegations of patent infringement, and have asserted that AB’s licensed patents are invalid.

From Illumina, Inc. 15 Oct 2009

Integrated Diagnostics launched to develop diagnostic tools and innovative biomarkers

Integrated Diagnostics launched officially today with more than $30 million in funding. A pre-eminent team of scientists and investors are behind the company, which was founded by renowned biotechnology innovator Dr. Leroy Hood. Integrated Diagnostics will focus on developing personalized and preventive diagnostics based on breakthroughs using genomic and proteomic technologies to identify organ-specific proteins.

14 Oct 2009

TGen selected to conduct cancer experiments using advanced computer simulations

SAIC-Frederick Inc., under its prime contract with the National Cancer Institute, has named the Translational Genomics Research Institute (TGen) as one of five national centers selected to conduct cancer experiments using advanced computer simulations.

9 Oct 2009

Arrayit Corporation CEO updates shareholders

With the start of trading of Arrayit Corporation (ARYC) on the bulletin board in March, 2009, we initiated a deliberate and measured strategy to introduce Arrayit's scientific accomplishments of the past 13 years to our shareholders. As we have laid the foundation for the announcement of future initiatives through this awareness campaign, we have seen interest in our stock steadily increase.

7 Oct 2009